## 3 Results
### Overall Survival Analysis According to the Combined Biomarker Expression
\begin{table}
\begin{tabular}{c c c c c} \hline \hline \multicolumn{5}{c}{**(A) Univariate Analysis of Own Cohort: SATB1\({}^{\text{n}}\)/SMAD3/Ezrin/\(\beta\)-Catenin**} \\ \hline \multirow{2}{*}{**Variable**} & \multirow{2}{*}{**HR**} & \multicolumn{2}{c}{**95\% CI**} & \multirow{2}{*}{\(p\) **Value**} \\ \cline{3-3} \cline{5-5}  & & & **Lower** & \\ \hline Others & \multicolumn{5}{c}{Ref.} \\ \hline SATB1\({}^{\text{n-high}}\)SMAD3\({}^{\text{low}}\)Ezrin\({}^{\text{low}}\)\(\beta\)-catenin\({}^{\text{low}}\) & 0.21 & 0.03 & 1.60 & 0.13 \\ \hline SATB1\({}^{\text{n-low}}\)SMAD3\({}^{\text{high}}\)Ezrin\({}^{\text{high}}\)\(\beta\)-catenin\({}^{\text{high}}\) & 2.16 & 1.03 & 4.52 & **0.04** \\ \hline \multicolumn{5}{c}{**(B) Univariate Analysis of Own Cohort:SATB1\({}^{\text{c}}\)/SMAD3 /Ezrin/\(\beta\)-Catenin**} \\ \hline \multirow{2}{*}{**Variable**} & \multirow{2}{*}{**HR**} & \multicolumn{2}{c}{**95\% CI**} & \multirow{2}{*}{\(p\) **Value**} \\ \cline{3-3} \cline{5-5}  & & **Lower** & & **Upper** \\ \hline Others & \multicolumn{5}{c}{Ref.} \\ \hline SATB1\({}^{\text{c}}\)-present\(\text{SMAD3}\)\({}^{\text{high}}\)Ezrin\({}^{\text{high}}\)\(\beta\)-catenin\({}^{\text{high}}\) & 3.06 & 1.27 & 7.36 & **0.01** \\ \hline SATB1\({}^{\text{c}}\)-absent\(\text{SMAD3}\)\({}^{\text{low}}\)Ezrin\({}^{\text{low}}\)\(\beta\)-catenin\({}^{\text{low}}\) & 0.26 & 0.08 & 0.86 & **0.03** \\ \hline \hline \end{tabular}
\end{table} 
Table 7: Univariate analysis of prognostic factors by the Cox proportional hazard model for combined expression. Figure 6: Overall survival analysis according to the combination of the panel (**A**) SATB1\({}^{\text{n}}\)/SMAD3/Ezrin/\(\beta\)-catenin, (**B**) SATB1\({}^{\text{c}}\)/SMAD3/Ezrin/\(\beta\)-catenin and (**C**) TCGA: SATB1/SMAD3/EzR/CTNNB1. \begin{table}
\begin{tabular}{c c c c c c} \hline \hline \multirow{2}{*}{**Variable**} & \multirow{2}{*}{**HR**} & \multicolumn{3}{c}{**95\% CI**} & \multirow{2}{*}{_p_ **Value**} \\ \cline{3-3} \cline{5-6}  & & \multicolumn{2}{c}{**Lower Upper**} & & \\ \hline Others & \multicolumn{6}{c}{Ref.} \\ \hline SATB1\({}^{\text{low}}\)SMAD3\({}^{\text{high}}\)EZr\({}^{\text{high}}\)CTNNB1\({}^{\text{high}}\) & 2.97 & 1.863 & 4.745 & **<0.0001** \\ \hline SATB1\({}^{\text{high}}\)SMAD3\({}^{\text{low}}\)EZr\({}^{\text{low}}\)CTNNB1\({}^{\text{low}}\) & 0.35 & 0.084 & 1.420 & 0.14 \\ \hline \hline \end{tabular}  
Significant \(p\) values (_p_ < 0.05) are marked in bold. Abbreviations: CI, confidence interval; HR, hazard ratio; TCGA—The Cancer Genome Atlas. (A) Univariate analysis of own cohort: SATB1\({}^{\text{n}}\)/SMAD3/Ezrin/\(\beta\)catenin:SATB1\({}^{\text{n}}\)highSMAD3\({}^{\text{low}}\)Ezrin\({}^{\text{low}}\)p-catenin\({}^{\text{low}}\) (_n_ = 5); SATB1\({}^{\text{n}}\)lowSMAD3\({}^{\text{high}}\)Ezrin\({}^{\text{high}}\)p-catenin\({}^{\text{high}}\) (_n_ = 9); Others (_n_ = 54). (B) Univariate analysis of own cohort: SATB1\({}^{\text{c}}\)/SMAD3/Ezrin/\(\beta\)catenin:SATB1\({}^{\text{c}}\)presentSMAD3\({}^{\text{high}}\)Ezrin\({}^{\text{high}}\)p-catenin\({}^{\text{high}}\) (_n_ = 6); SATB1\({}^{\text{c}}\)-otherSMAD3\({}^{\text{low}}\)Ezrinrin\({}^{\text{low}}\)p-catenin\({}^{\text{low}}\) (_n_ = 8); Others (_n_ = 54). (C) Univariate analysis of TCGA cohort: SATB1/SMAD3/EzR/CTNNB1:SATB1\({}^{\text{low}}\) SMAD3\({}^{\text{high}}\)EZr\({}^{\text{high}}\)CTNNB1\({}^{\text{low}}\) (_n_ = 12); Others (_n_ = 133).  
\end{table} 
Table 7: _Cont._